Viewing Study NCT07328802


Ignite Creation Date: 2026-03-26 @ 3:20 PM
Ignite Modification Date: 2026-03-31 @ 3:26 AM
Study NCT ID: NCT07328802
Status: NOT_YET_RECRUITING
Last Update Posted: 2026-01-09
First Post: 2025-06-19
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module